Portfolio Summary:
- Total Value: 100% (allocation only)
- Cash Position: ~56.4% of portfolio
- Portfolio Spread: Holdings in six companies, including new GeneDx Holdings (WGS)
- Performance: See snapshot table below for % gain/loss per position
Note: Portfolio is tracking staged buy opportunities in SLDP and RNA. COST (Costco) is also under consideration as a quality anchor for the future.
Current Holdings Snapshot
| Ticker | Company Name | Sector | Allocation (%) | Cost Basis | Current Price | Gain/Loss (%) |
|---|---|---|---|---|---|---|
| CRNX | Crinetics | Biotech | ~25.6% | $31.84 | $31.11 | -2.29% |
| VKTX | Viking Therapeutics | Biotech | ~11.9% | $27.73 | $32.01 | +15.43% |
| VNET | VNET Group | Data | ~2.2% | $7.00 | $9.01 | +28.71% |
| WGS | GeneDx Holdings | Genomics | ~3.9% | $80.00 | $77.87 | -2.66% |
| SLDP | Solid Power | Battery | 0% | $2.20 | $3.77 | 0.00% |
| RNA | Avidity Biosciences | Biotech | 0% | $28.00 | $33.76 | 0.00% |
| Cash | ~56.4% | |||||
Recent Activity
- New Position Added: Opened a small stake in GeneDx Holdings (WGS) for genomics exposure (now ~3.9%).
- Stable Positions: Core holdings remain intact across sectors, no trimming or selling this week.
- Maintained Cash Reserve: Over half of the portfolio in cash, preserving flexibility for coming earnings events.
Earnings Calendar & Upcoming Catalysts
| Symbol | Event | Date |
|---|---|---|
| VKTX | Earnings | July 23, 2025 |
| WGS | Earnings | July 29, 2025 |
Portfolio Insights
- CRNX: Largest allocation (~25.6%), slightly down YTD but remains a core conviction holding.
- VKTX: Strong momentum with a 15.4% gain since inclusion.
- VNET: Outperformed with +28.7%, leading sector gains.
- WGS: Newcomer, minor pullback since entry as the sector digests news.
- SLDP and RNA: Limit orders active for potential sizing, both at strategic entry prices.
Strategy & Risk Management
The portfolio emphasizes:
- Disciplined Entry: Staged limit orders, avoiding FOMO/chasing.
- High Cash Allocation: ~56% cash for optionality around volatile events.
- Diversification: Initiating new allocations (e.g. WGS) to spread sector exposure.
- Long-Term View: Accepting short-term volatility in pursuit of innovation and growth.
Looking Ahead
- Upcoming earnings from VKTX and WGS will be watched closely.
- Limit orders stay active for SLDP and RNA at pre-set entry points.
- Cash remains ready for opportunistic new buys or portfolio rebalance as opportunities arise.
Thank you for following the FlightToWealth moonshot portfolio update. The approach remains focused on discipline and innovation, with an emphasis on privacy by sharing only percentage allocations and performance.
Disclaimer: This update is for informational purposes only and does not constitute financial advice. Investing involves risks, including risk of principal loss. Always do your own research or consult a professional before making investment decisions.